Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Hypothesis coming from the subgroup analysis

Oral Oncol. 2023 Feb:137:106275. doi: 10.1016/j.oraloncology.2022.106275. Epub 2022 Dec 19.

Authors

Francesca De Felice¹, Paolo Bossi²

Affiliations

¹ Radiation Oncology, Policlinico Umberto I, Department of Radiological, Oncological and Pathological Sciences, "Sapienza" University of Rome, Viale Regina Elena 326, 00161 Rome, Italy. Electronic address: francesca.defelice@uniroma1.it.
² Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health-Medical Oncology, University of Brescia, ASST-Spedali Civili, Brescia 25123, Italy.

PMID: 36542994
DOI: 10.1016/j.oraloncology.2022.106275

No abstract available

Keywords: Chemotherapy; First line; Head neck cancer; Immunotherapy; Metastasis.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Squamous Cell* / pathology
Head and Neck Neoplasms* / drug therapy
Humans
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / pathology
Squamous Cell Carcinoma of Head and Neck / drug therapy

Substances

pembrolizumab
Antibodies, Monoclonal, Humanized